IDEXX Laboratories Inc
IDXX
506.67
-8.74
-1.70%
IDEXX Laboratories Inc
US · IDXX
#543 by market cap
Listed 1970
506.67
-8.74
-1.70%
Live - 5344 symbols - heartbeat 139s ago
· 2026-10-08 05:47
Pre-market
506.00
-0.13%
After-hours
507.01
+0.07%
- Market cap
- 39.92B
- P/E (TTM)i
- 35.61
- P/Bi
- 24.75
- EPSi
- 13.08
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on IDXX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 8 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.6 percentage points.
Institutional ownership
- Held by institutions
- 97.01% -0.56pp
- Institutions
- 1,624 -8
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund83.19%
Hedge Fund3.87%
Public Company3.26%
Government Pension Fund2.96%
Private Company1.75%
Family Office/Trust0.58%
Sovereign Wealth Fund0.49%
Insurance Company0.41%
Individual/Insider0.26%
Other3.23%
Top holders as of 2026-06-30
BlackRock
10.37% · 8.17M sh
Vanguard Capital Management, LLC
7.11% · 5.60M sh
Vanguard Portfolio Management, LLC
4.95% · 3.90M sh
State Street Global Advisors
4.76% · 3.75M sh
Invesco Capital Management LLC
3.99% · 3.14M sh
Geode Capital Management, LLC
3.25% · 2.56M sh
Baron Capital Group, Inc.
2.51% · 1.98M sh
UBS Asset Management
1.62% · 1.28M sh
William Blair Investment Management, LLC
1.55% · 1.22M sh
Arrowstreet Capital, Limited Partnership
1.35% · 1.07M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 36 buys · 14 sells
| Name | Role | Stake |
|---|---|---|
| Jonathan Mazelsky | Chief Executive Officer | 0.11% |
| Brian McKeon | Chief Financial Officer | 0.03% |
| Nimrata Hunt | Executive Vice President of Strategy, Sector Development & Global Operations | 0.02% |
| Michael Erickson | Senior VP & GM of Point of Care Diagnostics | 0.02% |
| George Fennell | Senior VP and GM of Companion Animal Group Customer Facing Organization for Americas & Europe | 0.01% |
| Lawrence Kingsley | Independent Non-Executive Chairperson | 0.01% |
| Sophie Vandebroek | Independent Director | 0.01% |
| Michael Lane | Executive VP and GM of Reference Laboratories & Information Technology | 0.01% |
| Sharon Underberg | Executive VP, General Counsel, & Corporate Secretary | 0.01% |
| Andrew Emerson | Senior Vice President of Corporate and CAG Finance | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-03 | Lawrence Kingsley | Independent Non-Executive Chairperson | Derivative Exercise and Sale | -2,203 | $114.17–532.08 |
| 2026-08-19 | Andrew Emerson | Senior Vice President of Corporate and CAG Finance | Derivative Exercise and Sale | -86 | $178.26 |
| 2026-08-19 | Andrew Emerson | Senior Vice President of Corporate and CAG Finance | Derivative Exercise and Retained | +179 | $178.26 |
| 2026-07-29 | Joseph Hooley | Independent Director | Other Acquisition | +49 | $558.80 |
| 2026-05-31 | George Fennell | Senior VP and GM of Companion Animal Group Customer Facing Organization for Americas & Europe | Derivative Exercise and Sale | -284 | $566.79 |
| 2026-05-31 | George Fennell | Senior VP and GM of Companion Animal Group Customer Facing Organization for Americas & Europe | Derivative Exercise and Retained | +355 | -- |
| 2026-05-11 | Daniel Junius | Independent Director | Other Derivative Acquisition | +234 | -- |
| 2026-05-11 | Daniel Junius | Independent Director | Other Derivative Acquisition | +525 | $533.92 |
| 2026-05-11 | Bruce Claflin | Independent Director | Other Derivative Acquisition | +234 | -- |
| 2026-05-11 | Bruce Claflin | Independent Director | Other Derivative Acquisition | +525 | $533.92 |
| 2026-05-11 | Stuart Essig | Independent Director | Other Derivative Acquisition | +234 | -- |
| 2026-05-11 | Stuart Essig | Independent Director | Other Derivative Acquisition | +525 | $533.92 |
| 2026-05-11 | Joseph Hooley | Independent Director | Other Derivative Acquisition | +234 | -- |
| 2026-05-11 | Joseph Hooley | Independent Director | Other Derivative Acquisition | +525 | $533.92 |
| 2026-05-11 | Lawrence Kingsley | Independent Non-Executive Chairperson | Other Derivative Acquisition | +309 | -- |
| 2026-05-11 | Lawrence Kingsley | Independent Non-Executive Chairperson | Other Derivative Acquisition | +693 | $533.92 |
| 2026-05-11 | Sophie Vandebroek | Independent Director | Other Derivative Acquisition | +234 | -- |
| 2026-05-11 | Sophie Vandebroek | Independent Director | Other Derivative Acquisition | +525 | $533.92 |
| 2026-05-11 | Irene Chang Britt | Independent Director | Other Derivative Acquisition | +234 | -- |
| 2026-05-11 | Irene Chang Britt | Independent Director | Other Derivative Acquisition | +525 | $533.92 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 05:47:24 · For reference only, not investment advice and not tailored to your situation.